Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
US Army
Julphar
Citi
Harvard Business School
Farmers Insurance
Healthtrust
Cipla
Daiichi Sankyo

Generated: April 22, 2018

DrugPatentWatch Database Preview

IMITREX Drug Profile

« Back to Dashboard

When do Imitrex patents expire, and when can generic versions of Imitrex launch?

Imitrex is a drug marketed by Glaxosmithkline and is included in three NDAs.

The generic ingredient in IMITREX is sumatriptan. There are twenty-four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the sumatriptan profile page.
Drug patent expirations by year for IMITREX
Medical Subject Heading (MeSH) Categories for IMITREX
Synonyms for IMITREX
(3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide
(3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide #
1-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide
1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide
1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide
1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methyl-methanesulfonamide
1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide
103628-46-2
103628-48-4 (succinate)
1H-Indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-N-methyl-
3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide
3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole -5-methanesulphonamide
3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide
3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide
3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide
628S462
8R78F6L9VO
AB0016356
AB00698285_14
AB00698285_15
AB00698285-12
AB00698285-13
AC1L1K6B
AJ-08373
AKOS015894924
Ambap103628-46-2
AN-5271
API0004291
AVP 825
AVP-825
AVP825
BDBM50005835
BIDD:GT0248
BRD-K50938287-001-01-7
BRN 6930870
BSPBio_002304
C07319
C14H21N3O2S
CAS-103628-46-2
CCG-230331
CHEBI:10650
CHEMBL128
D00451
D0Z6UC
DB00669
DR001144
DSSTox_CID_3628
DSSTox_GSID_23628
DSSTox_RID_77118
DTXSID4023628
FT-0631027
GR 43175
GR 43175X
GR-43175
GR43175
GTPL54
HE291385
HMS2231B21
HMS3369A05
HSDB 7742
I06-0076
Imigran (TN)
Imigran Recovery
Imitrex (TN)
Imitrex Oral
Imitrex, Imigran ,Treximet
J-001014
KB-217141
KQKPFRSPSRPDEB-UHFFFAOYSA-N
KS-1116
L000584
LS-83175
MCULE-3991948648
MLS001195659
MLS001304742
MolPort-002-885-863
NCGC00095838-01
NCGC00095838-02
NCGC00095838-03
NCGC00095838-04
NP101
O262
Onzetra Xsail
SBI-0206837.P001
SC-18016
SCHEMBL1482
SMR000596517
SPECTRUM1505372
STL451003
Sumatran
sumatriptan
Sumatriptan (JAN/USP/INN)
Sumatriptan [USP:INN:BAN]
Sumatriptanum
Sumatriptanum [INN-Latin]
Sumax
Tox21_111528
Tox21_111528_1
UNII-8R78F6L9VO
Zecuity
Zembrace SymTouch
ZINC14360

US Patents and Regulatory Information for IMITREX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline IMITREX sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-001 Dec 28, 1992 AP RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline IMITREX sumatriptan succinate TABLET;ORAL 020132-001 Jun 1, 1995 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline IMITREX sumatriptan SPRAY;NASAL 020626-003 Aug 26, 1997 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline IMITREX STATDOSE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-002 Feb 1, 2006 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for IMITREX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline IMITREX sumatriptan SPRAY;NASAL 020626-001 Aug 26, 1997 ➤ Sign Up ➤ Sign Up
Glaxosmithkline IMITREX sumatriptan SPRAY;NASAL 020626-001 Aug 26, 1997 ➤ Sign Up ➤ Sign Up
Glaxosmithkline IMITREX sumatriptan succinate TABLET;ORAL 020132-002 Jun 1, 1995 ➤ Sign Up ➤ Sign Up
Glaxosmithkline IMITREX sumatriptan SPRAY;NASAL 020626-001 Aug 26, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for IMITREX
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 6 mg/0.5 mL, 0.5 mL (prefilled syringes) ➤ Subscribe 2006-05-09
➤ Subscribe Injection 6 mg/0.5 mL, 0.5 mL vials ➤ Subscribe 2004-10-25

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
QuintilesIMS
Harvard Business School
Chinese Patent Office
Cantor Fitzgerald
McKinsey
Moodys
Dow
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.